Guatemala clinical trial regulatory guide
Regulator: MSPAS / DRCPFA (Ministerio de Salud Pública y Asistencia Social (MSPAS), Departamento de Regulación y Control de Productos Farmacéuticos y Afines (DRCPFA))
In Guatemala, clinical trials in humans are authorized by MSPAS through DRCPFA under Ministerial Agreement 206-2021. An authorized ethics committee approves the study before the application is presented to DRCPFA (sections 37.8 and 42). The agreement includes Phase I drug requirements (section 45.1) and a separate dossier for medical-device investigations (section 43). Guatemala has about 18.7 million people (World Bank, 2025), more than the Dominican Republic at about 11.5 million. This guide cites no completed bioaccess® study in Guatemala. Sources: medicamentos.mspas.gob.gt (official) and the World Bank (population).
Approval process
- Ethics committee approval. An authorized ethics committee in research approves the study before the application is presented to DRCPFA (sections 37.8 and 42). The official MSPAS portal lists the authorized committees.
- DRCPFA application. Present the signed authorization form and the dossier listed in section 42 after the ethics review. For a Phase I drug study, section 45.1 lists the additional requirements. Device investigations follow the dossier in section 43.
- DRCPFA authorization. DRCPFA issues the authorization within 30 business days of receiving complete documentation. If it asks for more information, the applicant has 15 business days to respond, and the final authorization follows within 15 business days of receiving that information (section 47).
- Supply of investigational product. The sponsor does not supply the investigational product to the investigator or institution until the required documentation, including the ethics committee and DRCPFA approvals, is in hand (section 103.1).
Ethics requirements
- Approval by an authorized ethics committee in research before the file goes to DRCPFA
- Informed consent, and assent where applicable
- Participant insurance before the trial starts (section 11)
- Each committee sets its own procedures, meeting frequency, and maximum response time
Documentation requirements
- Signed application form and the dossier listed in section 42, with the current MSPAS forms
- Protocol written in Spanish (section 42.11)
- Investigator brochure, which may be in its original language with a Spanish summary (section 42.12)
- For Phase I drug studies, the items in section 45.1, including prior animal toxicity information
Device registration
A clinical-trial authorization and a commercial MSPAS device registration are different files. Commercial registration is not a study permit and follows current MSPAS rules. bioaccess® does not sell a holder subscription in Guatemala.
FDA acceptance of Guatemala data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when that rule's conditions are met, including ethics-committee oversight and informed consent. Eligibility is not clearance or approval.
Key contacts
- MSPAS / DRCPFA — Ministry of Public Health and Social Assistance, clinical trial authorization
Frequently asked questions
Who authorizes clinical trials in Guatemala?
MSPAS, through DRCPFA, under Ministerial Agreement 206-2021. An authorized ethics committee approves the study first.
How long does DRCPFA take?
Section 47 allows up to 30 business days after DRCPFA receives complete documentation, plus 15 business days for the applicant to answer a query and 15 business days for the final decision. That period is not an ethics-committee clock or a startup promise.
Must the dossier be in Spanish?
The protocol must be written in Spanish. The investigator brochure may be in its original language with a Spanish summary. Confirm the language rule for the rest of the dossier.
Can Guatemala data support FDA submissions?
Foreign data can be eligible under 21 CFR 812.28 when its conditions are met. Eligibility is not clearance or approval.
All Latin America regulatory guides · Book a free 30-min strategy call